DYNDyne Therapeutics, Inc.

Nasdaq dyne-tx.com


$ 25.70 $ 0.04 (0.16 %)    

Wednesday, 08-May-2024 15:59:57 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 25.69
$ 25.28
$ 0.00 x 0
$ 25.71 x 100
$ 25.04 - $ 25.70
$ 6.40 - $ 30.27
464,277
na
2.08B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 10-30-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-02-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-dyne-therapeutics-maintains-31-price-target

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $31 price target.

 oppenheimer-reiterates-outperform-on-dyne-therapeutics-maintains-47-price-target

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...

 hc-wainwright--co-reiterates-buy-on-dyne-therapeutics-maintains-36-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price tar...

 morgan-stanley-initiates-coverage-on-dyne-therapeutics-with-overweight-rating-announces-price-target-of-40

Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announc...

 oppenheimer-reiterates-outperform-on-dyne-therapeutics-maintains-47-price-target

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 aehr-test-systems-reports-preliminary-results-joins-dyne-therapeutics-united-airlines-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

 neuromuscular-focused-avidity-biosciences-has-complete-package---analyst-predicts-stellar-142-stock-surge

Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising trea...

 chardan-capital-maintains-buy-on-dyne-therapeutics-raises-price-target-to-31

Chardan Capital maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $20 to $31.

 guggenheim-maintains-buy-on-dyne-therapeutics-raises-price-target-to-37

Guggenheim analyst Debjit Chattopadhyay maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from...

 hc-wainwright--co-reiterates-buy-on-dyne-therapeutics-maintains-36-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price tar...

 stifel-maintains-buy-on-dyne-therapeutics-raises-price-target-to-41

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $35 to $41.

 piper-sandler-maintains-overweight-on-dyne-therapeutics-raises-price-target-to-29

Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target...

 oppenheimer-reiterates-outperform-on-dyne-therapeutics-raises-price-target-to-47

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price targ...

 dyne-therapeutics-q4-eps-109-misses-092-estimate-cash-balance-of-1231m

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(...

 cooper-companies-reports-upbeat-results-joins-dell-netapp-tidewater-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION